Kristin Price, MS, CGC is a Senior Product Director at Guardant Health, a precision oncology company pioneering innovations across the cancer care continuum—from early detection to tools for treatment selection and monitoring in advanced-stage disease. Kristin leads the global product strategy for Guardant’s ctDNA monitoring portfolio, working closely with academic researchers and biopharma partners to advance and validate the clinical utility of liquid biopsy in improving patient outcomes. With over a decade of experience spanning clinical genetics, genomics, and product strategy, Kristin has been instrumental in developing and commercializing innovative ctDNA-based solutions. She has co-authored multiple high-impact publications. Kristin holds an MS in Molecular, Cellular, and Developmental Biology and Genetics from the University of Minnesota and is a board-certified genetic counselor.

Dr. Kuldeep Neote is the incoming CEO of Diadem Biotherapeutics. He is also an Entrepreneur-In-Residence (EIR) at the NIH/NIA. He has held EIR positions at UHN Commercialization and OICR/FACIT and focused on developing commercialization strategies to translate discoveries and creating Biotech spinouts. He also consults for the life sciences healthcare sector, with an extensive background in implementing cutting edge scientific discoveries into practical drug discovery programs. Previously, he was Vice President, External Innovation and responsible for Eli Lilly’s New Venture initiative where he focused on novel therapeutic licensing opportunities and enabled Lilly’s acquisition of Prevail Therapeutics. From 2013-2018, he was Sr. Director, New Ventures at J&J Innovation and responsible for creating New Venture opportunities. He has established several collaborations including two opportunities in Canada and served as the interim Head of JLABS@Canada. Prior to these leadership roles, he was in the Global External R&D at Eli Lilly and responsible for Oncology in-licensing opportunities.

Marc Buyse is a leading expert in clinical research and biostatistics, known for pioneering methodologies in personalized medicine, meta-analysis, and surrogate endpoints. As the founder of One2Treat, he drives innovation in trial design and analysis, developing SaaS solutions that prioritize patient needs and clinical relevance.

Murray Abramson, MD, MPH is a visionary and entrepreneurial professional with extensive experience in clinical operations and drug development. He earned his B.S. in Chemistry with honors and his M.D. from Duke University, followed by a clinical fellowship in infectious disease and a role as Chief Resident in the Department of Medicine at Duke University Medical Center.

Dr. Abramson spent 13 years at Merck, where he held various clinical, operational, and leadership positions, and later joined Biogen as VP of Global Clinical Operations, overseeing strategic planning and execution of clinical trials across all phases and indications. Subsequently, he was SVP, head of clinical innovation at Tempus AI. Murray is currently SVP, head of Clinical Development and Medical Affairs at Precision Biosciences. He also co-hosted a bi-weekly webcast for ALS patients and care providers for Everything ALS.

TBA

Samit Bhatt serves as Vice President of Myonex’s global Clinical Trial Patient Solutions (CTPS) division, where he drives innovation and execution in CTRx Services globally. Under his leadership, Myonex optimizes medication access for clinical trials in local markets while enhancing the experience for both trial sites and patients. With over 15 years of experience as a pharmacist, Samit Bhatt has held key roles in market access and clinical trials. He holds a Doctor of Pharmacy (PharmD) and an MBA from Drake University.

Dr. Scranton received his BA from the University of Tennessee and his Medical Degree from the Quillen College of Medicine at Eastern Tennessee State University.  He completed his Internal Medicine training at the Naval Medical Center in Portsmouth, where he served as the Chief Resident and Assistant Clinical Professor of Medicine at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences.  He completed his Harvard General Medicine Fellowship and received an MPH from the Harvard School of Public Health and was appointed as a Senior Research Fellow at the Massachusetts Veterans Administration Epidemiology, Research and Information Center (MAVERIC).  He was appointed as Assistant Professor at the Division of Aging at Brigham and Women’s Hospital and served as the Associate Medical Director and research consultant for Phase V Technology.  He then served as CMO at Veroscience where he led the efforts leading to the FDA approval of a first in class treatment for type 2 diabetes. Dr. Scranton joined Pacira Pharmaceutical where he also served as the CMO and led the global development and advancement of EXPAREL a non-opioid long lasting injectable local anesthetic.   Dr. Scranton now serves as the Chief Operating Officer and Chief Medical Officer at Lyndra Therapeutics where he is responsible for the global development of their pioneering weekly oral platform delivery technology.  Dr. Scranton has 15-years of combined federal service having served as a clinician, mentor, educator, administrator and researcher and 25 years of clinical and drug development research experience. 

Erik has 10+ years of pharma experience at Novartis, IQVIA, the Swiss Army and holds an MMedSc in Health Informatics from Karolinska Institute. After years of manually compiling trial data for sponsors, Erik co-founded Rivia to solve the invisible barrier to breakthroughs: fragmented and cumbersome trials through AI-driven analytics.